#USA #New York #Rosen Law Firm #SEC Fraud #Unicycive Therapeutics

Investors Call to Action

Overview of the Opportunity

The Rosen Law Firm, a prominent global firm dedicated to investor rights, is reaching out to individuals who purchased securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) during a defined period from March 29, 2024, to June 27, 2025. This communication addresses the critical lead plaintiff deadline set for October 14, 2025, and encourages potential class members to consider participating in a class action lawsuit that has already been initiated.

Understanding Your Rights

Investors who bought Unicycive stocks during the aforementioned period may qualify for financial compensation. Importantly, this participation comes with zero upfront costs due to a contingency fee arrangement — meaning you do not have to pay out-of-pocket fees until any financial recovery is secured. It is important for all affected individuals to understand their rights and the potential for compensation without incurring additional risks.

How to Join the Class Action

Those interested in joining the lawsuit can do so by visiting the Rosen Law Firm's dedicated web page: Join the Class Action. Alternative contact methods include reaching Phillip Kim, Esq. at the toll-free number 866-767-3653 or via email at [email protected]. It is essential to act fast, as only those who file motions by the October 14 deadline can be considered for the role of lead plaintiff, a position that entails representing the interests of other class members during the litigation.

Why Choose Rosen Law Firm

Selecting the right legal representation is critical in the face of securities fraud claims. The Rosen Law Firm stands out due to its proven success in handling class action lawsuits, particularly in securities-related matters. This firm has secured the largest-ever securities class action settlements against various companies, establishing itself as a leading authority in this field. By prioritizing investor interests and achieving significant financial recoveries, the firm has been exceptionally recognized in legal rankings like the ISS Securities Class Action Services, frequently being noted among the top firms for securities class action settlement achievements.

Details of the Allegations

The class action stems from allegations that Unicycive Therapeutics made misleading public statements that inflated their performance and regulatory compliance capabilities. More specifically, the lawsuit points to claims regarding Unicycive's fulfillment of U.S. Food and Drug Administration (FDA) manufacturing requirements, which were overstated. It was argued that these statements were not only misleading but materially false, resulting in investor losses once the truth was disclosed to the market.

The ramifications of these allegations could impact many investors significantly, emphasizing the importance of collective action in response to corporate injustices that put investor funds at risk.

Next Steps

Potential class members currently have the option to either participate actively in the lawsuit by becoming a lead plaintiff or remain passive members of the class. Regardless of the chosen path, it remains crucial for all investors affected by the events surrounding Unicycive Therapeutics to stay updated and consider their legal options carefully. An update regarding class certification will be provided in due course, and until then, retaining a preferred counsel is advised should any investor wish to pursue their legal rights independently.

Follow for Updates

To remain informed on developments regarding this class action and other relevant securities law matters, follow the Rosen Law Firm on LinkedIn, Twitter, and Facebook. Participation or simply staying aware could be vital during this substantial legal process affecting Unicycive Therapeutics investors.

For more information, potential plaintiffs can visit Rosen Legal or contact the firm directly at the details provided in this notice.